0.42

4.46% -0.021

Applied Therapeutics Inc (APLT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$0.441

Aprire:

$0.421

Volume 24 ore:

1.59M

Relative Volume:

0.46

Capitalizzazione di mercato:

$48.11M

Reddito:

Utile/perdita netta:

$-119.76M

Rapporto P/E:

-0.3111

EPS:

-1.35

Flusso di cassa netto:

$-55.17M

1 W Prestazione:

-22.40%

1M Prestazione:

-8.16%

6M Prestazione:

-94.64%

1 anno Prestazione:

-93.21%

Intervallo 1D:

$0.3952

$0.4391

Intervallo di 1 settimana:

$0.3952

$0.5598

Portata 52W:

$0.3952

$10.62

Applied Therapeutics Inc Stock (APLT) Company Profile

Nome

Applied Therapeutics Inc

Settore

Healthcare (1161)

Industria

Biotechnology (676)

Telefono

212-220-9226

Indirizzo

545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY

Dipendente

Cinguettio

@Applied_Tx

Prossima data di guadagno

2025-03-31

Ultimi documenti SEC

APLT's Discussions on Twitter

Confronta APLT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
APLT Applied Therapeutics Inc	0.4201	48.11M	0	-119.76M	-55.17M	-1.35
VRTX Vertex Pharmaceuticals Inc	486.78	125.55B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	611.89	67.78B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	588.49	36.24B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	261.18	33.99B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.90	28.77B	3.81B	-644.79M	-669.77M	-6.24

Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-23	Downgrade	William Blair	Outperform → Mkt Perform
2024-12-02	Downgrade	UBS	Buy → Neutral
2024-11-29	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2024-07-31	Iniziato	William Blair	Outperform
2024-03-26	Iniziato	RBC Capital Mkts	Outperform
2024-02-22	Iniziato	Leerink Partners	Outperform
2022-01-04	Downgrade	Barclays	Overweight → Equal Weight
2021-08-27	Downgrade	Goldman	Neutral → Sell
2021-06-25	Ripresa	Goldman	Neutral
2020-10-08	Iniziato	Truist	Buy
2020-04-22	Iniziato	Goldman	Buy
2020-02-27	Iniziato	Barclays	Overweight
2019-06-10	Iniziato	Citigroup	Buy
2019-06-10	Iniziato	Cowen	Outperform
2019-06-10	Iniziato	Robert W. Baird	Outperform

Mostra tutto

Applied Therapeutics Inc Borsa (APLT) Ultime notizie

09:46 AM

APLT stock touches 52-week low at $0.42 amid sharp annual decline - Investing.com

09:46 AM

Apr 01, 2025

Charles Schwab Investment Management Inc. Has $600,000 Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

Apr 01, 2025

Mar 31, 2025

Applied Therapeutics Delays Yearly Report Filing - TipRanks

Mar 31, 2025

Applied Therapeutics files Form 12b-25 with SEC - TipRanks

Mar 31, 2025

Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission - GlobeNewswire

Mar 31, 2025

Applied Therapeutics Requests SEC Extension: What This Means for 2024 Financial Results - Stock Titan

Mar 31, 2025

146,900 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Purchased by Swiss National Bank - Defense World

Mar 31, 2025

Mar 22, 2025

Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire

Mar 22, 2025

Lost Money on Applied Therapeutics, Inc.(APLT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

Mar 22, 2025

Mar 21, 2025

Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire

Mar 21, 2025

APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Mar 21, 2025

Mar 19, 2025

Applied Therapeutics appoints new Chief Regulatory Officer By Investing.com - Investing.com South Africa

Mar 19, 2025

Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer - citybiz

Mar 19, 2025

APLT DEADLINE ALERT: Applied Therapeutics Investors have until February 18 before Expiration of the Class Action DeadlineContact BFA Law if You Lost Money - Louisiana First News

Mar 19, 2025

Applied Therapeutics Names Todd Baumgartner As Chief Regulatory Officer - Nasdaq

Mar 19, 2025

Applied Therapeutics appoints new Chief Regulatory Officer - Investing.com

Mar 19, 2025

Applied Therapeutics Strengthens Drug Approval Push With 12-Time FDA Success Veteran - Stock Titan

Mar 19, 2025

Mar 16, 2025

Brokerages Set Applied Therapeutics, Inc. (NASDAQ:APLT) Price Target at $6.10 - MarketBeat

Mar 16, 2025

Mar 13, 2025

Applied Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your RightsAPLT - ACCESS Newswire

Mar 13, 2025

Applied Therapeutics, Inc. (NASDAQ:APLT) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Mar 13, 2025

Mar 12, 2025

APPLIED THERAPEUTICS Earnings Preview: Recent $APLT Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 12, 2025

A look into Applied Therapeutics Inc (APLT)’s deeper side - SETE News

Mar 12, 2025

Mar 09, 2025